Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:
“Off the press
- mOS 13.0 vs 11.4
- 48-mo OS rate 11.8% vs 4.3%
- great to report 4yr OS data in BTC.”
Title: Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer.
A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.
Authors: Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Rebecca Griffin, Julie Wang, Ioannis Xynos, Arndt Vogel, Juan W. Valle
Other articles about advanced biliary tract cancer on OncoDaily.